Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

78.69 -0.51 (-0.64%)
Streaming Delayed Price Updated: 1:35 PM EST, Dec 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 656,571
Open 79.66
Bid (Size) 78.69 (100)
Ask (Size) 78.80 (200)
Prev. Close 79.20
Today's Range 77.86 - 80.51
52wk Range 35.95 - 87.50
Shares Outstanding 79,931,766
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 ↗
Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
PTC Therapeutics offers strong growth and solid financials at a fair price, making it an attractive stock for investors seeking affordable expansion opportunities. 
Via Chartmill

Performance

YTD
+71.5%
+71.5%
1 Month
+15.8%
+15.8%
3 Month
+50.1%
+50.1%
6 Month
+61.2%
+61.2%
1 Year
+51.1%
+51.1%

More News

Read More
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
Via The Motley Fool
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
PTC Therapeutics Earnings Preview ↗
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows Strong Growth Momentum and Technical Health ↗
Via Chartmill
News headline image
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
Via MarketMinute
Topics Death
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Mix of Strong Growth and Bullish Technical Setup ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech ↗
Via Chartmill
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
Via Benzinga
News headline image
Here's Why Shares in PTC Therapeutics Soared This Week ↗
Via The Motley Fool
News headline image
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump ↗
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided ↗
Via Stocktwits
News headline image
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns ↗
Via Benzinga
News headline image
PTCT Earnings Beat but Sales Drop 4% ↗
Via The Motley Fool
Topics Earnings
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Reports Q2 2025 Earnings Beat with Narrowed Loss and Strong Sephience™ Launch ↗
Via Chartmill
Topics Earnings
News headline image
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics ↗
Via Benzinga
News headline image
These Analysts Increase Their Forecasts On PTC Therapeutics ↗
Via Benzinga
News headline image
FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened ↗
Via Stocktwits

Frequently Asked Questions

Is PTC Therapeutics, Inc. - Common Stock publicly traded?
Yes, PTC Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does PTC Therapeutics, Inc. - Common Stock trade on?
PTC Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PTC Therapeutics, Inc. - Common Stock?
The ticker symbol for PTC Therapeutics, Inc. - Common Stock is PTCT on the Nasdaq Stock Market
What is the current price of PTC Therapeutics, Inc. - Common Stock?
The current price of PTC Therapeutics, Inc. - Common Stock is 78.69
When was PTC Therapeutics, Inc. - Common Stock last traded?
The last trade of PTC Therapeutics, Inc. - Common Stock was at 12/02/25 01:35 PM ET
What is the market capitalization of PTC Therapeutics, Inc. - Common Stock?
The market capitalization of PTC Therapeutics, Inc. - Common Stock is 6.29B
How many shares of PTC Therapeutics, Inc. - Common Stock are outstanding?
PTC Therapeutics, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.